home / stock / ymab / ymab quote
Last: | $11.43 |
---|---|
Change Percent: | 0.53% |
Open: | $11.43 |
Close: | $11.37 |
High: | $11.59 |
Low: | $11.2414 |
Volume: | 41,697 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$11.43 | $11.43 | $11.37 | $11.59 | $11.2414 | 41,697 | 07-03-2024 |
$11.37 | $11.66 | $11.37 | $11.71 | $11.165 | 375,769 | 07-02-2024 |
$11.83 | $12.01 | $11.83 | $12.32 | $11.77 | 383,437 | 07-01-2024 |
$12.08 | $13.07 | $12.08 | $13.07 | $11.76 | 1,349,380 | 06-28-2024 |
$12.33 | $12.08 | $12.33 | $12.5 | $11.85 | 177,775 | 06-27-2024 |
$12.03 | $12.16 | $12.03 | $12.215 | $11.79 | 229,023 | 06-26-2024 |
$12.24 | $11.97 | $12.24 | $12.355 | $11.92 | 172,474 | 06-25-2024 |
$12.1 | $12.05 | $12.1 | $12.24 | $11.71 | 177,789 | 06-24-2024 |
$12 | $11.82 | $12 | $12.03 | $11.675 | 359,085 | 06-21-2024 |
$11.75 | $11.81 | $11.75 | $11.91 | $11.58 | 227,313 | 06-20-2024 |
$11.91 | $11.78 | $11.91 | $12 | $11.58 | 184,103 | 06-19-2024 |
$11.91 | $11.78 | $11.91 | $12 | $11.58 | 184,103 | 06-18-2024 |
$11.75 | $11.81 | $11.75 | $11.96 | $11.525 | 313,417 | 06-17-2024 |
$11.91 | $11.94 | $11.91 | $12.04 | $11.72 | 432,139 | 06-14-2024 |
$12.05 | $12.02 | $12.05 | $12.24 | $11.945 | 150,701 | 06-13-2024 |
$12.02 | $12.34 | $12.02 | $12.54 | $11.7 | 186,974 | 06-12-2024 |
$12.01 | $12.07 | $12.01 | $12.07 | $11.66 | 237,257 | 06-11-2024 |
$12.07 | $11.83 | $12.07 | $12.13 | $11.775 | 361,744 | 06-10-2024 |
$11.98 | $12.2 | $11.98 | $12.55 | $11.81 | 242,420 | 06-07-2024 |
$12.31 | $12.73 | $12.31 | $12.92 | $12.13 | 384,406 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
Y-mAbs Therapeutics Inc. Website:
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financi...